Are there any recommended genetic screening protocols for patients with a

There are currently no formal, standardised genetic screening protocols recommended by UK guidelines specifically for patients with a family history of dry age-related macular degeneration (AMD). UK guidance highlights that dry AMD has a strong hereditary/genetic predisposition combined with environmental and systemic factors, and a family history of AMD raises risk but does not guarantee disease development; thus routine genetic testing is not standard practice in clinical care for dry AMD cases NICE CKS,NICE NG82.

Genetic screening may be considered in selected cases, such as those with early onset AMD or atypical presentations that suggest hereditary macular dystrophies, to differentiate these from typical age-related disease given overlap in clinical features and genetic susceptibility Faustine & Bastion MC 2026. The complex genetic basis involves polymorphisms in complement pathway genes (e.g., complement factor H) and other loci like ARMS2, but these do not yet translate into actionable screening advancements incorporated into routine NHS pathways NICE CKS,NICE NG82 Faustine & Bastion MC 2026.

UK guidelines do emphasise clinical evaluation with slit-lamp biomicroscopy and optical coherence tomography (OCT) for diagnosis and monitoring rather than genetic testing NICE CKS,NICE NG82. Referral to specialist ophthalmology services is based chiefly on clinical findings and disease severity. Genetic counselling may be offered in cases with strong family history or suspicions of inherited macular dystrophies; however, universal genetic testing for dry AMD risk stratification is not currently advised or commissioned NICE NG82.

Emerging research from large cohorts including the Age-Related Eye Disease Study (AREDS) shows the potential for genetic and multimodal imaging data integration to improve risk prediction models and inform personalised medicine in AMD Prasad et al. 2026. Despite this, validation and translation of genetic biomarkers into clinical screening protocols remain an area for future development rather than present standard care.

In summary, although genetic susceptibility plays a key role in dry AMD and familial risk is acknowledged, current UK clinical practice does not recommend routine genetic screening in patients with family history of dry AMD but advises thorough clinical assessment and consideration of genetic counselling in special circumstances NICE CKS,NICE NG82 Prasad et al. 2026.